ArticleBrain research2014
Methylene blue treatment delays progression of perfusion-diffusion mismatch to infarct in permanent ischemic stroke.
Article in Brain research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02380573 (Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Methylene blue modulates functional connectivity in the human brain.Brain imaging and behavior · 2017Trial
- Effect of Methylene Blue on White Matter Injury after Ischemic Stroke.Oxidative medicine and cellular longevity · 2021Article
- Methylene Blue Reduces Neuronal Apoptosis and Improves Blood-Brain Barrier Integrity After Traumatic Brain Injury.Frontiers in neurology · 2019Article
- From Mitochondrial Function to Neuroprotection-an Emerging Role for Methylene Blue.Molecular neurobiology · 2018Review
- Chronic oral methylene blue treatment in a rat model of focal cerebral ischemia/reperfusion.Brain research · 2018Article
- Preventing the return of fear using reconsolidation updating and methylene blue is differentially dependent on extinction learning.Scientific reports · 2017Article
- Intraarterial transplantation of human umbilical cord blood mononuclear cells in hyperacute stroke improves vascular function.Stem cell research & therapy · 2017Article
- Methylene blue and normobaric hyperoxia combination therapy in experimental ischemic stroke.Brain and behavior · 2016Article
- Delayed Methylene Blue Improves Lesion Volume, Multi-Parametric Quantitative Magnetic Resonance Imaging Measurements, and Behavioral Outcome after Traumatic Brain Injury.Journal of neurotrauma · 2016Article
- Methylene blue protects astrocytes against glucose oxygen deprivation by improving cellular respiration.PloS one · 2015Article
- Protection against neurodegeneration with low-dose methylene blue and near-infrared light.Frontiers in cellular neuroscience · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
Stroke is a leading cause of morbidity and mortality in the world. Low-dose methylene blue (MB), which has been used safely to treat methemoglobinemia and cyanide poisoning in humans, has energy enhancing and antioxidant properties. We tested the hypothesis that methylene blue treatment delays progression of at-risk tissue (ca. perfusion-diffusion mismatch) to infarct in permanent middle cerebral artery occlusion in rats at two MB treatment doses. Serial MRI was used to evaluate MB treatment efficacy. The major findings were: (i) MB significantly prolonged the perfusion-diffusion mismatch, (ii) MB mildly increased the CBF in the hypoperfused tissue, (iii) MB did not change the final infarct volume in permanent ischemic stroke, and (iv) there were no dose-dependent effects on mismatch progression for the 1 and 3mg/kg doses studied. This neuroprotective effect is likely the result of sustained ATP production and increased CBF to tissue at risk. This work has the potential to readily lead to clinical stroke trials given MB's excellent safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.